Jane Street Group, LLC I Mab Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.18 - $3.06 $150,144 - $389,357	127,241 New	127,241 $167,000
Q1 2023 May 15, 2023	SELL	$3.08 - $7.39 $148,927 - $357,328	-48,353 Reduced 65.63%	25,319 $87,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $237,223 - $358,045	73,672 New	73,672 $307,000
Q2 2022 Aug 16, 2022	SELL	$8.27 - $18.43 $120,502 - $268,543	-14,571 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$12.54 - $46.93 $1.73 Million - $6.49 Million	-138,272 Reduced 90.47%	14,571 $236,000
Q3 2021 Nov 16, 2021	BUY	$57.18 - $84.43 $7.72 Million - $11.4 Million	134,977 Added 755.5%	152,843 $11.1 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $855,066 - $1.5 Million	17,866 New	17,866 $1.5 Million
Q1 2021 May 18, 2021	SELL	$44.38 - $63.97 $383,176 - $552,316	-8,634 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$32.94 - $47.15 $284,403 - $407,093	8,634 New	8,634 $407,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.